Phase 2 Study of Temozolomide to Treat Poor Risk / Refractory Acute Myeloid Leukemia; ODM derived from:


Versions (1) ▾
  1. 3/7/17
Uploaded on:

March 7, 2017

No DOI assigned. To request one pleaselog in.
Creative Commons BY 4.0
Model comments:

You can comment on the data model here. Via the speech bubbles at the itemgroups and items you can add comments to those specificially.

Itemgroup comments for:

Item comments for:

In order to download data models you must be logged in. Please log in or register for free.

Eligibility Leukemia, Myeloid NCT00611247

Eligibility Leukemia, Myeloid NCT00611247

Inclusion Criteria
1. patients must have histologically or cytologically confirmed acute myeloid leukemia, as defined by the who classification.
2. patients must be considered unfit for conventional induction chemotherapy, unwilling to receive such treatment or have evidence of disease relapse or refractory disease.
3. for patients who have received no prior conventional chemotherapy, one of the following must be present:
poor risk cytogenetics (complex abnormalities, deletions of chromosome 7 or 5, 11q23 abnormalities, inv[3])
secondary leukemia (prior hematologic disorder or therapy-related leukemia).
4. age > 60 years of age.
5. life expectancy of greater than 3 months.
6. ecog performance status greater than 2.
7. patients must have normal organ and marrow function as defined below:
8. adequate hepatic function: total bilirubin 1.5mg/dl, ast(sgot)/alt(sgpt) 2.5 x institutional upper limit of normal.
9. adequate renal function: serum creatinine within normal institutional limits or calculated creatinine clearance > 60 ml/min/1.73 m2 for patients with creatinine levels above institutional normal.
10. ability to understand and the willingness to sign a written informed consent document.
Exclusion Criteria
1. patients who have had chemotherapy or radiotherapy within 4 weeks (6 weeks for nitrosoureas or mitomycin c) prior to entering the study or those who have not recovered from adverse events due to agents administered more than 4 weeks earlier.
2. patients may not be receiving any other investigational agents.
3. history of allergic reactions attributed to compounds of similar chemical or biologic composition to temozolomide or dtic
4. history of gastrointestinal disease or significant bowel resection that could interfere with drug absorption.
5. uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements.
6. prior allogeneic stem cell transplantation.
7. inability to swallow tablets
8. prior radiation up to more than 25% of bone marrow.